Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, anticipates multiple clinical trial milestones in 2024.
The company's lead drug candidate is UX143 (setrusumab), a monoclonal antibody, for the treatment of Osteogenesis Imperfecta, commonly referred to as brittle bone disease, a hereditary bone condition.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.